Activation of c-ras oncogenes by mutations and amplification

L Sistonen; K Alitalo

Activation of c-ras oncogenes by mutations and amplification

Biochemistry and Cell Biology

Research output: Contribution to journal › Review Article or Literature Review › peer-review

Abstract

About 15% of all human tumours, including carcinomas, sarcomas, melanomas and leukaemias, contain c-ras oncogenes, which can be detected by a variety of methods. The activating lesion in the c-ras oncogenes is most often a point mutation affecting certain critical amino acid residues of its protein product. The clinical significance of c-ras oncogenes is not yet clear.

Original language	English
Pages (from-to)	297-303
Number of pages	7
Journal	Annals of Clinical Research
Volume	18
Issue number	5-6
Publication status	Published - 1986
MoE publication type	A2 Review article in a scientific journal

Keywords

Animals
Cell Transformation, Neoplastic
Gene Amplification
Gene Expression Regulation
Humans
Mutation
Oncogenes
Proto-Oncogenes

Cite this

@article{76eab64ae58840198feb527492cb5a69,

title = "Activation of c-ras oncogenes by mutations and amplification",

abstract = "About 15% of all human tumours, including carcinomas, sarcomas, melanomas and leukaemias, contain c-ras oncogenes, which can be detected by a variety of methods. The activating lesion in the c-ras oncogenes is most often a point mutation affecting certain critical amino acid residues of its protein product. The clinical significance of c-ras oncogenes is not yet clear.",

keywords = "Animals, Cell Transformation, Neoplastic, Gene Amplification, Gene Expression Regulation, Humans, Mutation, Oncogenes, Proto-Oncogenes",

author = "L Sistonen and K Alitalo",

year = "1986",

language = "English",

volume = "18",

pages = "297--303",

journal = "Annals of Clinical Research",

issn = "0003-4762",

number = "5-6",

}

TY - JOUR

T1 - Activation of c-ras oncogenes by mutations and amplification

AU - Sistonen, L

AU - Alitalo, K

PY - 1986

Y1 - 1986

N2 - About 15% of all human tumours, including carcinomas, sarcomas, melanomas and leukaemias, contain c-ras oncogenes, which can be detected by a variety of methods. The activating lesion in the c-ras oncogenes is most often a point mutation affecting certain critical amino acid residues of its protein product. The clinical significance of c-ras oncogenes is not yet clear.

AB - About 15% of all human tumours, including carcinomas, sarcomas, melanomas and leukaemias, contain c-ras oncogenes, which can be detected by a variety of methods. The activating lesion in the c-ras oncogenes is most often a point mutation affecting certain critical amino acid residues of its protein product. The clinical significance of c-ras oncogenes is not yet clear.

KW - Animals

KW - Cell Transformation, Neoplastic

KW - Gene Amplification

KW - Gene Expression Regulation

KW - Humans

KW - Mutation

KW - Oncogenes

KW - Proto-Oncogenes

M3 - Review Article or Literature Review

C2 - 3551775

SN - 0003-4762

VL - 18

SP - 297

EP - 303

JO - Annals of Clinical Research

JF - Annals of Clinical Research

IS - 5-6

ER -

Activation of c-ras oncogenes by mutations and amplification

Abstract

Keywords

Fingerprint

Cite this